DNAJC5 and malaria: The R21/Matrix-M malaria vaccine (which has an overall protection rate of 75%) was listed as a pre-qualified vaccine by the World Health Organization (WHO) in December 2023; as such, it is the second malaria vaccine to be authenticated by WHO after pre-qualification of the RTS, S/AS01 (overall protection rate = 55.1%, both vaccines are designed to target the circumsporozoite protein (CSP).